WHC is still in active development. Read this to understand our approach.
depiction of RUJBDQSFYCKFAA-UHFFFAOYSA-N.svg
isomerdesign

Tofisopam

Check on isomerdesign

drugmap

Dextofisopam

Check on drugmap

drugmap

Dextofisopam

Check on drugmap

wiki

Tofisopam

Check on wiki

Data

InChI: InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3

Synonyms: Tofisopam (JP17/INN), SCHEMBL43522, 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine,Tofisopam, DSSTox_GSID_23681, Seriel,tofisopam, BRD-A69095630-001-01-1, Grandaxin, Tofisopam (patented in japan), Nodeprine, 345T477, AKOS025401672, DSSTox_RID_77145, DB-045872, BCP09600, NCGC00165912-03, Tofisopam [INN:DCF:JAN], CCRIS 8738, Q-201839, D01254, DB08811, NCGC00165912-01, EGYT 341, NCGC00165912-02,R-Tofisopam, CAS-22345-47-7, Emandaxin (TN), Tox21_112269, CHEBI:32241, SCHEMBL8086894, Dextofisopam (USAN/INN), 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine, Q945537, FT-0638212, tofizopam, benzodiazepine, 22345-47-7, X6663, AC-24288, 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine, Tofisopam, >=98% (HPLC), solid, Egyt 341,1-(3,4-Dimethoxyphenyl)-7,8-dimethoxy-5-ethyl-4-methyl-5H-2,3-benzodiazepine, Tofisopamum, DTXSID3023681, QC-1212, 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine, EINECS 244-922-3, (1Z,3Z)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine, 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine, CHEMBL404216, MFCD00823171, Tofisopamum [INN-Latin], LS-14948, DSSTox_CID_3681

Estimated data

Solubility: -5.677 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 60.0% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.